Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects.
Chronic obstructive pulmonary disease (COPD) is pulmonary emphysema characterized by blockage in the airflow resulting in the long-term breathing problem, hence a major cause of mortality worldwide. Excessive generation of free radicals and the development of chronic inflammation are the major two e...
| Published in: | BioMed Research International pp. 1 - 14 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | pictorial review tables/charts Journal Article |
| Published: |
Wiley-Blackwell
3/11/2022
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155725323&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155725323 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 3/11/2022 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 155725323 155725323 155725323 10.1155/2022/5058121 155725323 ppf: 1 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects. aug: au: Saxena, Juhi Bisen, Monish Misra, Aditya Srivastava, Vijay Kumar Kaushik, Sanket Siddiqui, Arif Jamal Mishra, Neetu Singh, Abhijeet Jyoti, Anupam affil: Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Mohali, Punjab 140413, India sug: subj: Pulmonary Disease, Chronic Obstructive Drug Therapy Nanoparticles Utilization Lactic Acid Metabolism Patient Safety Nanoparticle Drug Delivery System Chronic Disease Inflammation Gene Expression Antibiotics Antiviral Agents Antioxidants Antineoplastic Agents ab: Chronic obstructive pulmonary disease (COPD) is pulmonary emphysema characterized by blockage in the airflow resulting in the long-term breathing problem, hence a major cause of mortality worldwide. Excessive generation of free radicals and the development of chronic inflammation are the major two episodes underlying the pathogenesis of COPD. Currently used drugs targeting these episodes including anti-inflammatory, antioxidants, and corticosteroids are unsafe, require high doses, and pose serious side effects. Nanomaterial-conjugated drugs have shown promising therapeutic potential against different respiratory diseases as they are required in small quantities which lower overall treatment costs and can be effectively targeted to diseased tissue microenvironment hence having minimal side effects. Poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) are safe as their breakdown products are easily metabolized in the body. Drugs loaded on the PLGA NPs have been shown to be promising agents as anticancer, antimicrobial, antioxidants, and anti-inflammatory. Surface modification of PLGA NPs can further improve their mechanical properties, drug loading potential, and pharmacological activities. In the present review, we have presented a brief insight into the pathophysiological mechanism underlying COPD and highlighted the role, potential, and current status of PLGA NPs loaded with drugs in the therapy of COPD. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|